AUTHOR=Wang Ling , Liu Kaiqun , Tan Xiao , Zhou Lin , Zhang Yuxin , Liu Xiaoning , Fu Yue , Qiu Wei , Yang Hui 

TITLE=Remedial Effect of Intravenous Cyclophosphamide in Corticosteroid-Refractory Patients in the Acute Phase of Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis

JOURNAL=Frontiers in Neurology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2020.612097

DOI=10.3389/fneur.2020.612097

ISSN=1664-2295

ABSTRACT=<p><bold>Background:</bold> To investigate the remedial efficacy and safety of intravenous cyclophosphamide (CP) in the acute phase in patients with neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) who are refractory to intravenous methylprednisolone (MP) treatment.</p><p><bold>Design:</bold> This study was a single-center, retrospective, observational case-control cohort study.</p><p><bold>Methods:</bold> Thirty-six patients who had acute NMOSD-ON attacks and were refractory to MP treatment were included. Patents were divided into two groups: the remedial CP group, and the MP group. The best-corrected visual acuity (BCVA), mean deviation (MD) of the visual field (VF), visual evoked potential amplitude (VEP-A), visual evoked potential latency (VEP-T), and average thickness of the retinal nerve fiber layer (RNFL) at onset, 1 month (m), 3 m, and 6 m after the attack were analyzed. Routine blood test results, liver and kidney function, routine urinalysis results and general condition were analyzed for safety issues at each follow-up. Fisher's exact test, the Mann-Whitney U test, the Kruskal-Wallis test and the Wilcoxon rank-sum test were used for statistical analysis.</p><p><bold>Results:</bold> The remedial CP group showed significant improvement over 6 m with regard to BCVA and MD (<italic>P</italic> &lt; 0.05),whereas MP group only showed significant improvement in MD (<italic>P</italic> &lt; 0.05). Regarding remedial CP intervention time window, the CP  ≤  30 days group showed significant improvement over 6 m with regard to BCVA (<italic>P</italic> = 0.002), MD (<italic>P</italic> = 0.003), and VEP-A (<italic>P</italic> = 0.036), while those CP &gt; 30 days group did not. Both two subgroups showed significantly RNFL thickness reduction, however, BCVA, MD, VEP-A, VEP-T, and RNFL thickness showed no significant differences between the two subgroups at any follow-up point (<italic>P</italic> &gt; 0.05).</p><p><bold>Conclusion:</bold> CP within 30 days of attack onset is safe and might have a beneficial degree of therapeutic efficacy for acute-phase treatment of NMOSD-ON that is refractory to MP treatment alone.</p>